JENSCARE-B (09877) announced that its transcatheter mitral valve repair (TMVr) system, JensClip, has recently formally submitted an application for CE Mark registration. This marks another product, following the LuX-Valve Plus transcatheter tricuspid valve replacement system, to successfully submit a CE Mark registration application, representing a significant step in the company's internationalization strategy. JensClip is an innovative medical device designed to treat severe mitral regurgitation, featuring simple and reliable operation. Its claw-wedge mechanical locking design allows for locking at any angle, ensuring stable and reliable leaflet coaptation, and is expected to effectively improve mitral regurgitation and reduce leaflet tension. The diamond-shaped valve clip design facilitates easy retrieval and repositioning, making the crossing procedure safer and effectively enhancing both the procedural safety and operational convenience; its integrated detachment design is anticipated to lower the potential risk of misoperation during a multi-step detachment process and effectively shorten the device operation time. The innovative design of JensClip has been patented globally. The one-year clinical follow-up results and challenging case application experiences for JensClip were presented at international academic conferences in 2025, including EuroPCR, TCT San Francisco, and PCR London Valves, where both its safety and effectiveness indicators demonstrated excellent performance, garnering widespread attention. Currently, JensClip has completed the submission of its registration application to the National Medical Products Administration in China and has been accepted; the one-year follow-up results are excellent, and it is currently in the registration review stage. JensClip has also successfully commenced clinical applications overseas. The company will actively promote the registration process for this product to meet broad clinical needs.
Comments